1. Introduction
1.1. Fibrosis
Fibrosis is a type of reactive process characterized by excessive accumulation of fibrous connective material in tissues or organs [ 1 ]. When tissues or organs are injured, a fibroma is formed during the healing process [ 2 ], through a series of processes called scarring. Though fibrosis can sometimes be resolved spontaneously [ 3 ], the most common types of fibrosis are tightly linked with pathologic states [ 2 ].
Fibrosis is initiated by stimulated fibroblasts, and circulating fibrocytes also contribute minimally [ 4 ]. Transforming growth factor (TGF)-β is the most well established pro-fibrotic signal [ 5 ], and is mainly secreted by macrophages responding to inflammation in injured tissues [ 6 ]. Other notable factors include tumor necrosis factor (TNF)-α [ 7 ], platelet-derived growth factor (PDGF) [ 8 ], basic fibroblast growth factor (bFGF) [ 9 ], and connective tissue growth factor (CTGF) [ 10 ]. These stimulants provoke fibroblast differentiation into myofibroblasts, which exacerbates extracellular matrix deposition [ 11 ]. The molecular pathway for fibroblast activation, SMAD phosphorylation, and subsequent SMAD nuclear translocation is well established [ 12 ]. The PI3K-AKT-mTOR signal cascade also contributes to fibroblast activation [ 13 ].
During fibrosis, epithelial–mesenchymal transition (EMT), a type of transdifferentiation of epithelial cells, is also an important step. Among the numerous intracellular regulators, the roles of SNAILs, basic helix-loop-helix (bHLH), and zinc-finger E box binding (ZEB) are well established in transdifferentiation of epithelial cells [ 14 ]. In terms of induction, TGF-β strongly promotes EMT. TGF-β causes transdifferentiation of epithelial cells predominantly through SMAD family signaling; however, PI3K-AKT-mTOR and RHOA pathways are also activated in response to TGF-β stimuli [ 14 ]. The specific mechanism of EMT is quite similar to fibroblast differentiation.
1.2. HDAC and HDAC Inhibitors
Histone deacetylases remove the acetyl moiety from histone tails [ 15 ]. Posttranslational modification of histone tails regulates transcriptional activity by modulating chromatin compaction [ 16 ]. Histone acetylation neutralizes the positive charge of lysine, which results in weakened binding of histones with DNA, resulting in less compacted DNA. On the other hand, histone deacetylation induces chromatin compaction. Removal of the acetyl group results in the tight association of the positively charged lysine with the negatively charged DNA. Hence, transcriptional activity is suppressed by histone deacetylation. Histone acetylation is mediated by histone acetyltransferases (HATs), whereas histone deacetylation is carried out by histone deacetylases (HDACs). HATs and HDACs finely regulate the histone acetylation status and thereby transcription.
Eighteen HDACs have been identified in mammals and are divided into four classes. HDAC1, -2, -3, and -8 are class I HDACs. HDAC4, -5, -6, -7, -9, and -10 are class II HDACs. HDAC6 and -10 contain two copies of the catalytic site. Recently, class II HDACs have been subgrouped as class IIa (HDAC4, -5, -7, and -9) and class IIb (HDAC6 and -10). The Sirtuin family (Sirt1-7) are classified as class III HDAC. HDAC11 is the only member of class IV HDAC. Class I, II, and IV HDACs require zinc ions to deacetylase their substrate and share a conserved functional deacetylation domain [ 17 ], suggesting that a single compound could inhibit all zinc-dependent HDACs simultaneously. Unlike zinc-dependent HDACs, sirtuins require NAD + to execute deacetylation. Specifically, class III HDACs can be suppressed by nicotinamides.
1.3. Functional Relevance of HDAC in Fibrogenesis
Previous reports have independently delineated the role of HDACs in the development of fibrosis. Even though the specific mechanism of HDAC is somewhat different, cumulative evidence indicates that HDACs accelerate fibrogenesis in a redundant manner and that HDAC inhibitors (HDACIs) successfully regulate fibrosis. We briefly summarize the therapeutic potential of HDACIs in fibrosis in Figure 1 .
According to HDACI studies, HDACs function as pro-inflammatory molecules that trigger secretion of pro-fibrotic cytokines [ 18 ]. HDACI interferes with expression and/or secretion of interleukin (IL)-1β [ 19 ], IL-6 (a master regulator in inflammation) [ 20 , 21 ], and TNF-α [ 22 ]. Zhu et al. observed that active HDAC3 specifically recruits NF-κB/p65 and thereby regulates TNF-α production in response to lipopolysaccharide stimulation [ 22 ]. In the next steps, various subtypes of HDACs are significantly associated with the inflammation process. In interferon gamma stimulated cells, HDACs accumulate in the promoter region and provoke the expression of genes required for the inflammatory response [ 23 ]. Specifically, HDAC1/2 and HDAC3 were identified as inflammatory regulators in epithelial cells [ 17 ] and in fibroblast-like synoviocytes [ 24 ], respectively. Increased expression of HDACs stimulates fibroblast differentiation into myofibroblasts [ 25 ]. During chronic inflammation, various cytokines from inflammatory sites stimulate myofibroblast differentiation, which indicates that anti-inflammatory properties could also regulate fibrosis in an indirect manner. However, many previous reports show evidence supporting the direct regulation by HDACs in myofibroblast differentiation [ 25 , 26 ]. To overcome the indirect effect of HDACI in vivo, fibroblasts were isolated and cultured in vitro. HDACI significantly reduced myofibroblast differentiation triggered by TGF-β. HDACs also incited extracellular matrix formation [ 27 ]. HDAC1 and HDAC2, as components of Sin3A, epigenetically blocked collagen synthesis in a synchronous manner [ 28 ]. At least at particular points, HDACs contribute in various ways in each step of fibrosis. Taken together, these results support the concept that inhibition of HDACs is important for inhibiting the progression of fibrosis.
1.4. HDAC Inhibitors and Their Therapeutic Potential
HDAC was first identified as a novel teratogenic factor [ 29 ]. Class I HDACs regulate cell proliferation in a redundant manner. HDACs are closely linked with tumorigenic features such as proliferation, distant metastasis, and aneuploidy [ 29 ], and, generally, increased expression of HDACs is linked with poor prognosis [ 30 , 31 ]. Hence, pharmacologic inhibition of HDACs could be a potential strategy in the development of cancer treatment. To date, at least four HDAC inhibitors (HDACIs) have been approved by the United States Food and Drug Administration (US FDA): Vorinostat (2006, Zolinza ® ), romidepsin (2009, Istodax ® ), belinostat (2014, Beleodaq ® ), and panobinostat (2015, Farydak ® ). An HDACI was approved for hematologic malignancy [ 15 , 29 ]. Vorinostat and romidepsin were approved for cutaneous T cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL). Belinostat was also approved for relapsing PTCL. Panobinostat was licensed for multiple myeloma. The overall remission rate with these HDACIs ranges about 20–30%. However, long-term survival benefits are limited [ 29 ]. HDACIs have been approved and highlighted as an emerging option for anticancer regimens. Massive clinical trials have been undertaken to expand the clinical indication of approved HDACIs or even de novo inhibitors for solid tumors. However, the overall survival benefits are quite limited [ 32 ]. Many research groups have delineated the role of HDACs in various human diseases as well as the beneficial effects of HDACIs in the animal models of those diseases. Beyond showing anticancer properties, HDACIs successfully ameliorated the progression of atherosclerosis [ 33 ], myocardial death by ischemia–reperfusion injury [ 34 ], Alzheimer’s disease development [ 35 ], inflammation [ 18 ], and fibrosis-associated diseases.
Fibrosis itself is a physiological reaction; however, deposition of fibrous material interferes with the normal functioning of organs or tissues [ 1 ]. Hence, proper control of fibrosis is important to maintain physiological organ functions. In the clinic, limited options are available to control progression of fibrosis-associated diseases. For example, glucocorticoids or tyrosine kinase inhibitors are prescribed for pulmonary fibrosis, but the therapeutic outcomes are still limited [ 36 ]. Most patients suffer from progressive deterioration of pulmonary function despite conventional treatment regimens. Developing novel therapeutics to alleviate fibrosis is an urgent medical issue. In this review, we summarize the possible benefits of HDACIs as novel regulators of tissue fibrosis. We briefly summarize the fibrosis-associated human diseases in Table 1 .
2. Experimental Outcomes of HDAC Inhibitors in Animal Models of Fibrosis-Associated Disease
2.1. Liver Cirrhosis
Liver cirrhosis involves chronic irreversible changes of the hepatic parenchyma to scar tissue, i.e., the process of fibrosis. Notable causes of liver cirrhosis include chronic alcohol consumption [ 53 , 54 ], non-alcoholic fatty liver disease [ 55 ], aflatoxin [ 56 ], and hepatitis virus infection [ 57 ]. Among the pathophysiologies of cirrhosis, chronic inflammation of the liver is a common underlying condition. Park et al. demonstrated an improvement of severity in liver cirrhosis and in the survival rate by the use of HDACIs [ 37 ]. Liver fibrosis was induced by bile duct ligation (BDL) in rats followed by administration of HDACIs. Activation of hepatic stellate cells (HSCs), the major source of hepatic myofibroblasts, was dramatically reduced in the HDACI-treatment group. HDACI arrested the cell cycle and even induced apoptosis in HSCs. HDACI ameliorated the hepatic dysfunction exacerbated by BDL and markedly improved the survival rate. Notably, the final outcome of HDACI treatment is superior to that of cyclooxygenase inhibition, indicating that HDACIs exert complex effects, including anti-inflammatory effects [ 29 , 37 ].
2.2. Cardiac Fibrosis
Accumulation of interstitial fibrosis in the heart aggravates cardiac dysfunction. The main function of the heart is supplying nutrition and oxygen to the peripheral tissues. Regular beating is thus mandatory for appropriate circulation. To control the series of sequential contractions, the heart has its own regulatory system controlled by an electronic drive generated in the sinoatrial (SA) node. Before contraction, the ventricle has to relax sufficiently to secure inflow of blood. In other words, efficient ventricular relaxation, or diastole, wherein the ventricular chamber is filled with blood, is important for effective pumping out, or systole. Cardiac fibrosis occurs in several conditions and results in secondary problems as follows.
Fibrosis in the atria disturbs normal conduction from the SA node [ 58 ]. Frequently, fibrotic foci generate additional autonomic signals, which are occasionally conducted to the ventricle resulting in arrhythmia [ 59 , 60 ]. Atrial arrhythmia itself results in both turbulence and stasis of blood and finally induces thrombosis, an important cause of cerebral infarction [ 61 ]. Furthermore, conduction of irregular beats to the ventricle is a notable cause of heart failure [ 62 ]. Fibrous material can also accumulate in the ventricle.
Cardiac hypertrophy is the major underlying mechanism of ventricular fibrosis [ 42 , 63 , 64 , 65 , 66 ]. Although cardiac hypertrophy is a kind of adaptive process to counter increased hemodynamics, chronic uncontrolled stimuli exacerbate microinflammation and myofibroblast differentiation. Fibrous changes in the ventricle might contribute to contractile force. However, they yield negative outcomes in the diastole phase, which is referred to as diastolic dysfunction [ 67 ]. Fibrosis-induced ventricular stiffness results in the failure of appropriate ventricular relaxation and decreases the ventricular blood volume. If diastolic dysfunction is not controlled, it can proceed to diastolic heart failure [ 68 ]. No effective drugs are available for diastolic heart failure. All clinical trials with beta blockers [ 69 ], angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) [ 70 , 71 ], or aldosterone antagonists [ 72 ] failed to show improved survival rates in diastolic heart failure patients [ 73 ].
HDACIs can successfully control both atrial fibrosis and ventricular fibrosis. Liu et al. clearly demonstrated that trichostatin A (TSA), a pan-HDAC inhibitor, alleviated atrial fibrosis and subsequent atrial fibrillation (AF) [ 44 ]. In addition, TSA normalized connexin 40 remodeling. HDAC inhibition reversed conduction abnormalities and atrial automaticity. Seki et al. developed a canine model for atrial arrhythmia and atrial fibrosis [ 45 ]. In addition to TSA, class I HDAC specific inhibitors were tested. Both pan-HDACIs and class I HDACIs ameliorated atrial fibrosis and AF. Overall cardiac function was also improved in the HDACI-administered group. Inflammatory cell infiltration was markedly reduced.
A genetic ablation study of HDAC provided direct evidence to understand the role of HDAC in arrhythmia. Montgomery et al. deleted both HDAC1 and HDAC2 and found that the L-type and T-type calcium subunits were dysregulated [ 66 ]. Cacna1h and Cacna2d2 were markedly increased in HDAC1 and HDAC2 double knockout mice and the mice presented with fatal cardiac arrhythmia. Meraviglia et al. treated primary rat cardiomyocyte cultures with HDACI and suberanilohydroxamic acid (SAHA), and measured calcium current [ 74 ]. SAHA-treatment in cardiomyocytes ameliorated intracellular calcium handling and contractile performance through acetylation of the sarcoplasmic reticulum protein calcium ATPase 2. Taken together, these data suggest class I HDACs play a pivotal role in the development of atrial fibrosis and atrial arrhythmia.
Both right and left ventricular fibrosis was well controlled by HDACIs; however, few studies have revealed the role of HDACs in right ventricular fibrosis. Cho et al. induced right ventricular hypertrophy with monocrotaline or by pulmonary artery constriction [ 43 ]. Unlike captopril, an ACE inhibitor, HDACI significantly suppressed the fibrotic changes in the right ventricle. There is limited evidence on right ventricular hypertrophy and fibrosis, and more detailed studies are required. Left ventricular hypertrophy and fibrosis have been repeatedly reported by various research groups [ 40 , 41 , 42 , 63 , 64 , 75 , 76 ]. Pan-HDACI or selective class I HDACI alleviate the development of hypertrophy and progression of fibrosis [ 40 , 41 , 42 ]. Long-term treatment with HDACI showed remarkable improvement in heart failure transition and cardiac fibrosis in a rodent model [ 41 , 64 ]. HDACIs are notable therapeutics for diastolic heart failure patients with cardiac fibrosis as the major underlying cause [ 77 ]. HDACIs ameliorated both hypertrophy and cardiac fibrosis simultaneously. Hence, it is not clear whether the anti-fibrotic effect of HDACI is a direct effect or an indirect outcome of improving hypertrophy. To answer this question, Yoon et al. isolated and cultured cardiac fibroblasts from adult mice and observed that myofibroblast differentiation by TGF-b is attenuated when HDAC2 is inhibited in vitro [ 76 ]. Taking these data together, we conclude that HDACIs can directly regulate cardiac fibrosis.
2.3. Pulmonary Fibrosis
Pulmonary fibrosis is characterized by a chronic irreversible decline in pulmonary function. Typical symptoms include dry cough, shortness of breath, and limitation of exercise [ 78 ]. When the cause of pulmonary fibrosis is not determined, patients are diagnosed with idiopathic pulmonary fibrosis (IPF) [ 79 ]. Air pollution, cigarette smoking, and viral infection are regarded as causes of pulmonary fibrosis. Thus far, effective regimens to block the progression of pulmonary fibrosis remain limited [ 80 ]. The common pathophysiology of pulmonary fibrosis includes chronic inflammation in the lung parenchyma and deposition of fibrous extracellular matrix, which finally results in thickening of the alveolar wall. In the case of a known underlying cause, the primary cause of disease should be controlled adequately. However, there is no reported cause of IPF, and inhibition of fibrosis is the only therapeutic strategy [ 80 , 81 ].
Notable studies have reported the therapeutic potential of HDACIs in IPF. Guo et al. utilized normal human lung fibroblasts (NHLF) and induced fibrosis using TGF-β [ 25 ]. TSA abrogated NHLF differentiation into myofibroblasts and small interfering RNA against HDAC4 blocked smooth muscle alpha actin accumulation. In a separate result, Coward et al. demonstrated that epigenetic abnormalities in cyclooxygenase-2 expression were restored by HDAC inhibition, which induces resistance to pulmonary fibrogenesis [ 47 ].
2.4. Renal Fibrosis
Renal fibrosis is also determined by aberrant growth of residential fibroblasts and accumulation of excess fibrous materials in the renal parenchyma. Renal fibrosis is often associated with glomerulonephritis [ 10 , 82 ], focal segmental glomerulosclerosis [ 83 ], IgA nephropathy [ 84 ], and diabetic nephropathy [ 85 ]. Commonly, loss of glomeruli and substitution of fibrotic foci is observed [ 86 ]. For the molecular signaling cascade, the roles of TGF-β/SMAD and signal transducer and activator of transcription (STAT) 3 are well established [ 86 , 87 ]. The rodent model for renal fibrosis induced by unilateral ureteral obstruction (UUO) is widely used [ 88 ]. Pan-HDACIs, such as TSA [ 48 , 49 , 89 ] or CG200745 [ 51 ], have been shown to exhibit a renoprotective effect. HDACIs alleviated glomerular destruction and aberrant expansion of interstitial fibrosis. Similar to the results obtained with the in vivo administration of HDACIs, STAT3 signal was inhibited in vitro by TSA in NRK49F, a rat kidney fibroblast cell-line [ 89 ]. Beside directly inhibiting fibroblast differentiation, HDACIs also regulate epithelial–mesenchymal transition. Noh et al. injected streptozotocin (STZ) to induce diabetes in rats and treated them with TSA. The HDACI potently decreased fibrotic changes in STZ-treated rats. To visualize the direct effect of TSA on fibrosis, a rat kidney epithelial cell line, NRK52E, was also utilized. Treatment with TGF-β in the culture medium successfully induced fibrosis in NRK52E cells, and TSA effectively prevented these changes. Through a series of studies, HDAC2 was indicated as a master regulator in renal fibrosis [ 52 ].
2.5. Miscellaneous Diseases
Polycystic kidney disease (PKD) is an inherited disease whose main characteristics include progressive growth of cysts [ 90 ]. In addition to the kidney, cyst formation simultaneously occurs in different organs such as the liver, pancreas, or aortic root, which results in aneurysms [ 91 ]. A variety of genetic mutations have been indicated to be responsible factors in PKD. Polycystin-1 (PKD1), polycystin-2 (PKD2), and GANAB (PKD3) [ 92 , 93 , 94 ] are also indicated. Chronic interstitial inflammation and consequent fibrosis is a major feature of PKD. Because PKD mainly arises from genetic problems, no established therapeutics are available [ 90 ]. Ultimately, kidney transplantation would be required in end-stage renal disease patients. Several studies have applied animal models for human PKD and tested various chemicals to suppress disease progression [ 95 , 96 , 97 ]. Pkd1 mutation induced robust upregulation of HDAC6, which induced cystic fibrosis transmembrane conductance regulator (CFTR) and fibroblast cell proliferation. Tubacin, an HDAC6-specific inhibitor, attenuated cyst formation in a rodent model. Renal function was also improved in the tubacin-treated group. Thus, an HDAC6-targeted approach could be considered as a therapeutic strategy for PKD in the future [ 95 ].
Cystic fibrosis is a hereditary disease that generates cysts of varying sizes in most parts of the body including the liver, lung, kidney, and intestines [ 98 ]. Life-threatening comorbidities includes repeated-pulmonary infection and difficulty in breathing [ 99 ]. Mutation in cystic fibrosis transmembrane conductance regulator (CFTR) is a major pathophysiology of this fatal genetic disorder. Specific deletion of phenylalanine 508 (∆F508) results in unconventional folding and removal of CFTR, total loss of which results in failure to maintain the osmotic gradient [ 98 ]. Several studies have revealed that HDACIs can be considered as a therapeutic target for cystic fibrosis [ 100 , 101 ]. Recently, Bodas et al. utilized a transient overexpression system in HEK293 cells with ∆F508-CFTR and tested several HDAC inhibition approaches such as SAHA, Tubacin, and HDAC6-shRNA [ 100 ]. HDACIs successfully restored the intracellular trafficking that was abolished by misfolding of ∆F508-CFTR. In the presence of HDACIs, proteosomal degradation due to unconventional accumulation of ∆F508-CFTR in endoplasmic reticulum was markedly reduced. Furthermore, chronic treatment of HDACIs restored ion current malfunction of ∆F508-CFTR [ 102 ]. Possible mechanism, how HDACIs specifically ameliorates channel function defect of ∆F508-CFTR was further supported by another report. Pankow et al. cultured bronchial epithelial cells and evaluated the functional complex of ∆F508-CFTR by use of SAHA treated cell. ∆F508-CFTR formed different complex from wild type CFTR, SAHA exerted interactome remodeling of ∆F508-CFTR. Finally, SAHA-exposed human primary bronchial epithelial cells carrying ∆F508-CFTR was able to successfully regulate osmosis [ 101 ]. Thus, targeting HDACI could be a management strategy for cystic fibrosis patients.
During surgical procedures, skin fibroblasts are easily activated and are deeply associated with scarring [ 103 ]. Most of the scar formation by fibrosis is not harmful but is a cosmetic problem. However, fibrosis in the eye may restrict vision or interfere with drainage of aqueous humor and hence might be fatal [ 104 ]. Trabeculectomy surgery is considered an option to release the increased ocular pressure [ 105 ]. The main purpose of trabeculectomy is to generate a drainage outflow track for the aqueous humor [ 105 ]. Scar formation around the outflow track halts drainage, indicating surgical failure. Hence, anti-fibrotic management is important to improve surgical outcomes. Eye drops with steroids are widely used after trabeculectomy intervention; however, fatal side effects of topical steroids have been reported, including wound infection, hypotony, and paradoxical elevation of intraocular pressure [ 106 , 107 ]. Sung et al. administered TSA in a rat trabeculectomy model and compared the results with the clinical outcome of the steroid administered group. Topical TSA dramatically reduced fibrosis and vascularity, as effectively as steroids, without any apparent corneal epithelial toxicity. HDACI could thus be an alternative modality to steroids after trabeculectomy surgery [ 108 ].
Hypertrophic scars, or keloids, are a fibrosis-associated disorder [ 103 ]. It is difficult to manipulate because surgical procedures or similar intervention could cause reaggravation. Despite a limited number of reports, HDACI could be a novel therapeutic option for keloid or hypertrophic scars. Fitzgerald et al. observed upregulation of HDAC2 in keloid scars [ 109 ]. Furthermore, Russell et al. found that epigenetic alteration in keloid fibroblasts was normalized after treatment with TSA [ 110 ]. Diao et al. injected TSA in hypertrophic scars and observed regression of a pre-established scar [ 111 ]. Taken together, these data indicate that topical administration of HDACI could be an effective method to control the overgrowth of skin fibroblasts.
3. Limitations and Future Perspectives
Multiple HDACs are involved in various kinds of human disease. Sometimes, more than two HDACs play an opposite role in the development of a single disease, suggesting that pan-HDACIs can result in unwanted effects. HDAC2, a class I HDAC, induces cardiac hypertrophy, whereas class IIa HDACs potently suppress that response [ 75 ]. To minimize adverse drug reactions, subtype specific inhibitors should be developed. HDAC1 and HDAC2, class I HDACs, are highly expressed in most cells, and molecular homology between HDAC1 and HDAC2 is quite high [ 112 , 113 ]. Furthermore, class I, II, and IV HDACs share a conserved catalytic domain, indicating that it is difficult to develop a subtype-specific inhibitor [ 15 , 16 , 29 ]. However, few HDACIs are available for subtype specific HDAC inhibition. Only HDAC6, a class IIb HDAC, can be specifically blocked by a single compound [ 114 ]. Otherwise, more than two HDACs are affected simultaneously.
Besides histones, numerous “non-histone” proteins undergo acetylation dynamics. For this reason, HDACIs simultaneously induce histone compaction by modulating histones as well as affecting enzyme activity by non-histone protein acetylation, which indicates that HDAC inhibition might contribute to fatal side effects. Our group already reported the toxic side effects of an HDACI in a vulnerable subject in vascular calcification. Thus, HDACI fatally accelerates calcium deposition [ 115 ]. Hence, indirect inhibition should be considered to bypass these issues. Our group treated cultured cardiac fibroblasts with an Hsp70 inhibitor to mimic the inactivation of HDAC2. Hsp70 inhibition effectively attenuated myofibroblast differentiation as did HDACI [ 76 ]. Use of an indirect method to suppress a certain type of HDAC after understanding the detailed pathophysiology could overcome the adverse drug reaction to HDACIs without loss of efficacy.
4. Conclusions
In this review, we briefly summarize multiple types of animal studies regarding human diseases that share chronic inflammation and tissue fibrosis as underlying mechanisms. Tissue fibrosis results in interference with normal organ function, and no therapeutics are currently available for the condition. Therefore, anti-fibrotic agents need to be urgently developed for increasing both quality of life and survival rate of patients with fibrosis and related conditions. Numerous reports have repeatedly demonstrated the therapeutic potential of HDACIs in animal models of fibrosis-associated human disease. Hence, to create additional therapeutic options, it may be worth considering clinical trials for these diseases using FDA-approved HDACI.
Acknowledgments
The authors would like to thank Hyun Kook, Chonnam National University Medical School, for his fruitful comments on the manuscript. Mirim Park, Sunyoung Park, Hangyeol Lee, and Hyeonjin Yang, Chonnam National University Medical School thoroughly read and made critical comments on the manuscript.
Author Contributions
Conceptualization; writing, preparing, reviewing, and editing the manuscript; and funding acquisition: S.Y., G.K., and G.H.E.
Funding
This research was funded by Chonnam National University Hospital Biomedical Research Institute Grant (CRI 16037-21) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2016R1A6A3A11933772).
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
References
1. Wynn T.A. Cellular and molecular mechanisms of fibrosis J. Pathol. 2008 214 199 210 10.1002/path.2277 18161745 PMC2693329
2. Pardali E. Sanchez-Duffhues G. Gomez-Puerto M.C. Ten Dijke P. TGF-beta-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases Int. J. Mol. Sci. 2017 18 2157 10.3390/ijms18102157 29039786 PMC5666838
3. Kisseleva T. Cong M. Paik Y. Scholten D. Jiang C. Benner C. Iwaisako K. Moore-Morris T. Scott B. Tsukamoto H. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis Proc. Nat. Acad. Sic. USA 2012 109 9448 9453 10.1073/pnas.1201840109 22566629 PMC3386114
4. Mehrad B. Burdick M.D. Wandersee N.J. Shahir K.S. Zhang L. Simpson P.M. Strieter R.M. Field J.J. Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease Blood Adv. 2017 1 2217 2224 10.1182/bloodadvances.2017010777 29296869 PMC5737132
5. Meng X.M. Nikolic-Paterson D.J. Lan H.Y. TGF-beta: The master regulator of fibrosis Nat. Rev. Nephrol. 2016 12 325 338 10.1038/nrneph.2016.48 27108839
6. Wynn T.A. Vannella K.M. Macrophages in Tissue Repair, Regeneration, and Fibrosis Immunity 2016 44 450 462 10.1016/j.immuni.2016.02.015 26982353 PMC4794754
7. Yang Y.M. Seki E. TNFalpha in liver fibrosis Curr. Pathobiol. Rep. 2015 3 253 261 10.1007/s40139-015-0093-z 26726307 PMC4693602
8. Klinkhammer B.M. Floege J. Boor P. PDGF in organ fibrosis Mol. Asp. Med. 2018 62 44 62 10.1016/j.mam.2017.11.008 29155002
9. Strutz F. Zeisberg M. Hemmerlein B. Sattler B. Hummel K. Becker V. Muller G.A. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation Kidney Int. 2000 57 1521 1538 10.1046/j.1523-1755.2000.00997.x 10760088
10. Toda N. Mukoyama M. Yanagita M. Yokoi H. CTGF in kidney fibrosis and glomerulonephritis Inflamm. Regen. 2018 38 14 10.1186/s41232-018-0070-0 30123390 PMC6091167
11. Yazdani S. Bansal R. Prakash J. Drug targeting to myofibroblasts: Implications for fibrosis and cancer Adv. Drug Deliv. Rev. 2017 121 101 116 10.1016/j.addr.2017.07.010 28720422
12. Walton K.L. Johnson K.E. Harrison C.A. Targeting TGF-beta Mediated SMAD Signaling for the Prevention of Fibrosis Front. Pharmacol. 2017 8 461 10.3389/fphar.2017.00461 28769795 PMC5509761
13. Lawrence J. Nho R. The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis Int. J. Mol. Sci. 2018 19 778 10.3390/ijms19030778 29518028 PMC5877639
14. Lamouille S. Xu J. Derynck R. Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. Cell. Biol. 2014 15 178 196 10.1038/nrm3758 24556840 PMC4240281
15. Eom G.H. Kook H. Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases Pharm. Ther. 2014 143 168 180 10.1016/j.pharmthera.2014.02.012 24594235
16. Eom G.H. Kook H. Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy BMB Rep. 2015 48 131 138 10.5483/BMBRep.2015.48.3.242 25388210 PMC4453031
17. Hammond C.M. Stromme C.B. Huang H. Patel D.J. Groth A. Histone chaperone networks shaping chromatin function Nat. Rev. Mol. Cell. Biol. 2017 18 141 158 10.1038/nrm.2016.159 28053344 PMC5319910
18. Hull E.E. Montgomery M.R. Leyva K.J. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases Biomed. Res. Int. 2016 2016 8797206 10.1155/2016/8797206 27556043 PMC4983322
19. Carta S. Tassi S. Semino C. Fossati G. Mascagni P. Dinarello C.A. Rubartelli A. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: Role of microtubules Blood 2006 108 1618 1626 10.1182/blood-2006-03-014126 16684958 PMC1895509
20. Makki M.S. Haqqi T.M. Histone deacetylase inhibitor vorinostat (SAHA, MK0683) perturb miR-9-MCPIP1 axis to block IL-1beta-induced IL-6 expression in human OA chondrocytes Connect. Tissue Res. 2017 58 64 75 10.1080/03008207.2016.1211113 27404795 PMC5233650
21. Glauben R. Sonnenberg E. Wetzel M. Mascagni P. Siegmund B. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo J. Biol. Chem. 2014 289 6142 6151 10.1074/jbc.M113.517599 24421314 PMC3937680
22. Zhu H. Shan L. Schiller P.W. Mai A. Peng T. Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation J. Biol. Chem. 2010 285 9429 9436 10.1074/jbc.M109.071274 20097764 PMC2843192
23. Klampfer L. Huang J. Swaby L.A. Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1 J. Biol. Chem. 2004 279 30358 30368 10.1074/jbc.M401359200 15123634
24. Angiolilli C. Kabala P.A. Grabiec A.M. Van Baarsen I.M. Ferguson B.S. Garcia S. Malvar Fernandez B. McKinsey T.A. Tak P.P. Fossati G. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes Ann. Rheum. Dis. 2017 76 277 285 10.1136/annrheumdis-2015-209064 27457515 PMC5264225
25. Guo W. Shan B. Klingsberg R.C. Qin X. Lasky J.A. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition Am. J. Phys. Lung Cell. Mol. Phys. 2009 297 L864 L870 10.1152/ajplung.00128.2009 PMC2777501 19700647
26. Glenisson W. Castronovo V. Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation Biochim. Biophys. Acta. 2007 1773 1572 1582 10.1016/j.bbamcr.2007.05.016 17610967
27. Saito S. Zhuang Y. Shan B. Danchuk S. Luo F. Korfei M. Guenther A. Lasky J.A. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFbeta-PI3K-Akt pathway PLoS ONE 2017 12 e0186615 10.1371/journal.pone.0186615 29045477 PMC5646855
28. Zheng Y. Khan Z. Zanfagnin V. Correa L.F. Delaney A.A. Daftary G.S. Epigenetic Modulation of Collagen 1A1: Therapeutic Implications in Fibrosis and Endometriosis Biol. Reprod. 2016 94 87 10.1095/biolreprod.115.138115 26935598
29. Yoon S. Eom G.H. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases Chonnam. Med. J. 2016 52 1 11 10.4068/cmj.2016.52.1.1 26865995 PMC4742605
30. Zhao H. Yu Z. Zhao L. He M. Ren J. Wu H. Chen Q. Yao W. Wei M. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy Jpn. J. Clin. Oncol. 2016 46 893 902 10.1093/jjco/hyw096 27432453
31. Zhou L. Xu X. Liu H. Hu X. Zhang W. Ye M. Zhu X. Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients J. Cancer 2018 9 4547 4555 10.7150/jca.26780 30519361 PMC6277648
32. Mottamal M. Zheng S. Huang T.L. Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents Molecules 2015 20 3898 3941 10.3390/molecules20033898 25738536 PMC4372801
33. Findeisen H.M. Gizard F. Zhao Y. Qing H. Heywood E.B. Jones K.L. Cohn D. Bruemmer D. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition Arterioscler. Thromb. Vasc. Biol. 2011 31 851 860 10.1161/ATVBAHA.110.221952 21233448 PMC3074344
34. Wang J. Hu X. Jiang H. HDAC inhibition: A novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling Int. J. Cardiol. 2015 190 126 127 10.1016/j.ijcard.2015.04.172 25918063
35. Yang S.S. Zhang R. Wang G. Zhang Y.F. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease Transl. Neurodegener. 2017 6 19 10.1186/s40035-017-0089-1 28702178 PMC5504819
36. Fujimoto H. Kobayashi T. Azuma A. Idiopathic Pulmonary Fibrosis: Treatment and Prognosis Clin. Med. Insights Circ. Respir. Pulm. Med. 2015 9 179 185 10.4137/CCRPM.S23321 27980445 PMC5147432
37. Park K.C. Park J.H. Jeon J.Y. Kim S.Y. Kim J.M. Lim C.Y. Lee T.H. Kim H.K. Lee H.G. Kim S.M. A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells Br. J. Pharmacol. 2014 171 4820 4830 10.1111/bph.12590 24467283 PMC4232907
38. Mannaerts I. Eysackers N. Onyema O.O. Van Beneden K. Valente S. Mai A. Odenthal M. van Grunsven L.A. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29 PLoS ONE 2013 8 e55786 10.1371/journal.pone.0055786 23383282 PMC3561334
39. Aher J.S. Khan S. Jain S. Tikoo K. Jena G. Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation Hum. Exp. Toxicol. 2015 34 44 55 10.1177/0960327114531992 24812151
40. Kee H.J. Sohn I.S. Nam K.I. Park J.E. Qian Y.R. Yin Z. Ahn Y. Jeong M.H. Bang Y.J. Kim N. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding Circulation 2006 113 51 59 10.1161/CIRCULATIONAHA.105.559724 16380549
41. Gallo P. Latronico M.V. Gallo P. Grimaldi S. Borgia F. Todaro M. Jones P. Gallinari P. De Francesco R. Ciliberto G. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure Cardiovasc. Res. 2008 80 416 424 10.1093/cvr/cvn215 18697792
42. Kong Y. Tannous P. Lu G. Berenji K. Rothermel B.A. Olson E.N. Hill J.A. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy Circulation 2006 113 2579 2588 10.1161/CIRCULATIONAHA.106.625467 16735673 PMC4105979
43. Cho Y.K. Eom G.H. Kee H.J. Kim H.S. Choi W.Y. Nam K.I. Ma J.S. Kook H. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats Circ. J. 2010 74 760 770 10.1253/circj.CJ-09-0580 20208383
44. Liu F. Levin M.D. Petrenko N.B. Lu M.M. Wang T. Yuan L.J. Stout A.L. Epstein J.A. Patel V.V. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin J. Mol. Cell. Cardiol. 2008 45 715 723 10.1016/j.yjmcc.2008.08.015 18926829 PMC2630487
45. Seki M. LaCanna R. Powers J.C. Vrakas C. Liu F. Berretta R. Chacko G. Holten J. Jadiya P. Wang T. Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation J. Pharmacol. Exp. Ther. 2016 358 441 449 10.1124/jpet.116.234591 27353074 PMC4998670
46. Sanders Y.Y. Hagood J.S. Liu H. Zhang W. Ambalavanan N. Thannickal V.J. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice Eur. Respir. J. 2014 43 1448 1458 10.1183/09031936.00095113 24603818
47. Coward W.R. Watts K. Feghali-Bostwick C.A. Knox A. Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis Mol. Cell. Biol. 2009 29 4325 4339 10.1128/MCB.01776-08 19487460 PMC2715818
48. Wu W.P. Tsai Y.G. Lin T.Y. Wu M.J. Lin C.Y. The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3(+)IL-17(+) T cells BMC Nephrol. 2017 18 225 10.1186/s12882-017-0630-6 28693431 PMC5504832
49. Tung C.W. Hsu Y.C. Cai C.J. Shih Y.H. Wang C.J. Chang P.J. Lin C.L. Trichostatin A ameliorates renal tubulointerstitial fibrosis through modulation of the JNK-dependent Notch-2 signaling pathway Sci. Rep. 2017 7 14495 10.1038/s41598-017-15162-6 29101337 PMC5670251
50. Marumo T. Hishikawa K. Yoshikawa M. Hirahashi J. Kawachi S. Fujita T. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury Am. J. Phys. Renal. Phys. 2010 298 F133 F141 10.1152/ajprenal.00400.2009 19906951
51. Choi H.S. Song J.H. Kim I.J. Joo S.Y. Eom G.H. Kim I. Cha H. Cho J.M. Ma S.K. Kim S.W. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease Sci. Rep. 2018 8 11546 10.1038/s41598-018-30008-5 30068917 PMC6070546
52. Noh H. Oh E.Y. Seo J.Y. Yu M.R. Kim Y.O. Ha H. Lee H.B. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury Am. J. Phys. Renal. Phys. 2009 297 F729 F739 10.1152/ajprenal.00086.2009 19553350
53. Barrio E. Tome S. Rodriguez I. Gude F. Sanchez-Leira J. Perez-Becerra E. Gonzalez-Quintela A. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome Alcohol. Clin. Exp. Res. 2004 28 131 136 10.1097/01.ALC.0000106301.39746.EB 14745311
54. Mohammed F. Alcoholic hepatitis N. Engl. J. Med. 2009 361 1512 1513 10.1056/NEJMc091513 19812414
55. Chalasani N. Younossi Z. Lavine J.E. Charlton M. Cusi K. Rinella M. Harrison S.A. Brunt E.M. Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Hepatology 2018 67 328 357 10.1002/hep.29367 28714183
56. Chu Y.J. Yang H.I. Wu H.C. Liu J. Wang L.Y. Lu S.N. Lee M.H. Jen C.L. You S.L. Santella R.M. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers Int. J. Cancer 2017 141 711 720 10.1002/ijc.30782 28509392 PMC5513813
57. Perz J.F. Armstrong G.L. Farrington L.A. Hutin Y.J. Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J. Hepatol. 2006 45 529 538 10.1016/j.jhep.2006.05.013 16879891
58. Francis Stuart S.D. De Jesus N.M. Lindsey M.L. Ripplinger C.M. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction J. Mol. Cell. Cardiol. 2016 91 114 122 10.1016/j.yjmcc.2015.12.024 26739214 PMC4764395
59. Everett T.H.t. Olgin J.E. Atrial fibrosis and the mechanisms of atrial fibrillation Heart Rhythm. 2007 4 S24 S27 10.1016/j.hrthm.2006.12.040 17336879 PMC1850572
60. Burstein B. Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation J. Am. Coll. Cardiol. 2008 51 802 809 10.1016/j.jacc.2007.09.064 18294563
61. January C.T. Wann L.S. Alpert J.S. Calkins H. Cigarroa J.E. Cleveland J.C. Jr. Conti J.B. Ellinor P.T. Ezekowitz M.D. Field M.E. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society Circulation 2014 130 e199 e267 10.1161/CIR.0000000000000041 24682347 PMC4676081
62. Kotecha D. Piccini J.P. Atrial fibrillation in heart failure: What should we do? Eur. Heart J. 2015 36 3250 3257 10.1093/eurheartj/ehv513 26419625 PMC4670966
63. Yoon S. Kook T. Min H.K. Kwon D.H. Cho Y.K. Kim M. Shin S. Joung H. Jeong S.H. Lee S. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart Exp. Mol. Med. 2018 50 83 10.1038/s12276-018-0121-2 30050113 PMC6062565
64. Eom G.H. Cho Y.K. Ko J.H. Shin S. Choe N. Kim Y. Joung H. Kim H.S. Nam K.I. Kee H.J. Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart Circulation 2011 123 2392 2403 10.1161/CIRCULATIONAHA.110.003665 21576649
65. Chang S. McKinsey T.A. Zhang C.L. Richardson J.A. Hill J.A. Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development Mol. Cell. Biol. 2004 24 8467 8476 10.1128/MCB.24.19.8467-8476.2004 15367668 PMC516756
66. Montgomery R.L. Davis C.A. Potthoff M.J. Haberland M. Fielitz J. Qi X. Hill J.A. Richardson J.A. Olson E.N. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility Genes Dev. 2007 21 1790 1802 10.1101/gad.1563807 17639084 PMC1920173
67. Kuwahara F. Kai H. Tokuda K. Kai M. Takeshita A. Egashira K. Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats Circulation 2002 106 130 135 10.1161/01.CIR.0000020689.12472.E0 12093782
68. Reed A.L. Tanaka A. Sorescu D. Liu H. Jeong E.M. Sturdy M. Walp E.R. Dudley S.C. Jr. Sutliff R.L. Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse Am. J. Phys. 2011 301 H824 H831 10.1152/ajpheart.00407.2010 21724869 PMC3191096
69. Hernandez A.F. Hammill B.G. O’Connor C.M. Schulman K.A. Curtis L.H. Fonarow G.C. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry J. Am. Coll. Cardiol. 2009 53 184 192 10.1016/j.jacc.2008.09.031 19130987 PMC3513266
70. Yusuf S. Pfeffer M.A. Swedberg K. Granger C.B. Held P. McMurray J.J. Michelson E.L. Olofsson B. Ostergren J. Investigators C. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial Lancet 2003 362 777 781 10.1016/S0140-6736(03)14285-7 13678871
71. Massie B.M. Carson P.E. McMurray J.J. Komajda M. McKelvie R. Zile M.R. Anderson S. Donovan M. Iverson E. Staiger C. Irbesartan in patients with heart failure and preserved ejection fraction N. Engl. J. Med. 2008 359 2456 2467 10.1056/NEJMoa0805450 19001508
72. Pitt B. Pfeffer M.A. Assmann S.F. Boineau R. Anand I.S. Claggett B. Clausell N. Desai A.S. Diaz R. Fleg J.L. Spironolactone for heart failure with preserved ejection fraction N. Engl. J. Med. 2014 370 1383 1392 10.1056/NEJMoa1313731 24716680
73. Paulus W.J. van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: An inconvenient truth! J. Am. Coll. Cardiol. 2010 55 526 537 10.1016/j.jacc.2009.06.067 20152557
74. Meraviglia V. Bocchi L. Sacchetto R. Florio M.C. Motta B.M. Corti C. Weichenberger C.X. Savi M. D’Elia Y. Rosato-Siri M.D. HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca(2+)-ATPase Activity in Cardiac Myocytes Int. J. Mol. Sci. 2018 19 419 10.3390/ijms19020419 29385061 PMC5855641
75. Eom G.H. Nam Y.S. Oh J.G. Choe N. Min H.K. Yoo E.K. Kang G. Nguyen V.H. Min J.J. Kim J.K. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy Circ. Res. 2014 114 1133 1143 10.1161/CIRCRESAHA.114.303429 24526703
76. Yoon S. Kim M. Min H.-K. Lee Y.-U. Kwon D.-H. Lee M. Lee S. Kook T. Joung H. Nam K.-I. Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2 Cardiovasc. Res. 2018 10.1093/cvr/cvy317 30596969
77. Schiattarella G.G. Hill J.A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload Circulation 2015 131 1435 1447 10.1161/CIRCULATIONAHA.115.013894 25901069 PMC4408778
78. Wilson M.S. Wynn T.A. Pulmonary fibrosis: Pathogenesis, etiology and regulation Mucosal. Immunol. 2009 2 103 121 10.1038/mi.2008.85 19129758 PMC2675823
79. Martinez F.J. Collard H.R. Pardo A. Raghu G. Richeldi L. Selman M. Swigris J.J. Taniguchi H. Wells A.U. Idiopathic pulmonary fibrosis Nat. Rev. Dis. Primers. 2017 3 17074 10.1038/nrdp.2017.74 29052582
80. Richeldi L. Collard H.R. Jones M.G. Idiopathic pulmonary fibrosis Lancet 2017 389 1941 1952 10.1016/S0140-6736(17)30866-8 28365056
81. Lederer D.J. Martinez F.J. Idiopathic Pulmonary Fibrosis N. Engl. J. Med. 2018 378 1811 1823 10.1056/NEJMra1705751 29742380
82. Timoshanko J.R. Kitching A.R. Semple T.J. Tipping P.G. Holdsworth S.R. A pathogenetic role for mast cells in experimental crescentic glomerulonephritis J. Am. Soc. Nephrol. 2006 17 150 159 10.1681/ASN.2005080799 16319187
83. Nogueira A. Pires M.J. Oliveira P.A. Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies In Vivo 2017 31 1 22 10.21873/invivo.11019 28064215 PMC5354133
84. Sakamoto-Ihara T. Suzuki Y. Kurusu A. Yamashita M. Horikoshi S. Tomino Y. Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy Inflamm. Res. 2007 56 421 427 10.1007/s00011-007-6145-z 18026699
85. Yamamoto T. Nakamura T. Noble N.A. Ruoslahti E. Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy Proc. N. Acad. Sci. USA 1993 90 1814 1818 10.1073/pnas.90.5.1814 PMC45970 7680480
86. Liu Y. Cellular and molecular mechanisms of renal fibrosis Nat. Rev. Nephrol. 2011 7 684 696 10.1038/nrneph.2011.149 22009250 PMC4520424
87. Duffield J.S. Beyond EMT: Epithelial STAT3 as a Central Regulator of Fibrogenesis J. Am. Soc. Nephrol. 2016 27 3502 3504 10.1681/ASN.2016060603 27371721 PMC5118497
88. Chevalier R.L. Forbes M.S. Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy Kidney Int. 2009 75 1145 1152 10.1038/ki.2009.86 19340094
89. Pang M. Kothapally J. Mao H. Tolbert E. Ponnusamy M. Chin Y.E. Zhuang S. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy Am. J. Phys. Renal. Phys. 2009 297 F996 F1005 10.1152/ajprenal.00282.2009 PMC2775583 19640900
90. Wilson P.D. Polycystic kidney disease N. Engl. J. Med. 2004 350 151 164 10.1056/NEJMra022161 14711914
91. Kim J.A. Blumenfeld J.D. Chhabra S. Dutruel S.P. Thimmappa N.D. Bobb W.O. Donahue S. Rennert H.E. Tan A.Y. Giambrone A.E. Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations Radiology 2016 280 762 770 10.1148/radiol.2016151650 27046073 PMC5006734
92. Mochizuki T. Wu G. Hayashi T. Xenophontos S.L. Veldhuisen B. Saris J.J. Reynolds D.M. Cai Y. Gabow P.A. Pierides A. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein Science 1996 272 1339 1342 10.1126/science.272.5266.1339 8650545
93. Boucher C. Sandford R. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2) Eur. J. Hum. Gen. 2004 12 347 354 10.1038/sj.ejhg.5201162 14872199
94. Porath B. Gainullin V.G. Cornec-Le Gall E. Dillinger E.K. Heyer C.M. Hopp K. Edwards M.E. Madsen C.D. Mauritz S.R. Banks C.J. Mutations in GANAB, Encoding the Glucosidase IIalpha Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease Am. J. Hum. Gen. 2016 98 1193 1207 10.1016/j.ajhg.2016.05.004 27259053 PMC4908191
95. Cebotaru L. Liu Q. Yanda M.K. Boinot C. Outeda P. Huso D.L. Watnick T. Guggino W.B. Cebotaru V. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease Kidney Int. 2016 90 90 99 10.1016/j.kint.2016.01.026 27165822 PMC4912414
96. Yanda M.K. Liu Q. Cebotaru V. Guggino W.B. Cebotaru L. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease J. Biol. Chem. 2017 292 17897 17908 10.1074/jbc.M117.803775 28887310 PMC5663887
97. Cao Y. Semanchik N. Lee S.H. Somlo S. Barbano P.E. Coifman R. Sun Z. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models Proc. N. Acad. Sci. USA 2009 106 21819 21824 10.1073/pnas.0911987106 19966229 PMC2799791
98. Cutting G.R. Cystic fibrosis genetics: From molecular understanding to clinical application Nat. Rev. Gen. 2015 16 45 56 10.1038/nrg3849 25404111 PMC4364438
99. Klimova B. Kuca K. Novotny M. Maresova P. Cystic Fibrosis Revisited—A Review Study Med. Chem. 2017 13 102 109 10.2174/1573406412666160608113235 27292156
100. Bodas M. Mazur S. Min T. Vij N. Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses Respir. Res. 2018 19 2 10.1186/s12931-017-0705-8 29301535 PMC5755330
101. Pankow S. Bamberger C. Calzolari D. Martinez-Bartolome S. Lavallee-Adam M. Balch W.E. Yates J.R. 3rd F508 CFTR interactome remodelling promotes rescue of cystic fibrosis Nature 2015 528 510 516 10.1038/nature15729 26618866 PMC4826614
102. Hutt D.M. Herman D. Rodrigues A.P. Noel S. Pilewski J.M. Matteson J. Hoch B. Kellner W. Kelly J.W. Schmidt A. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis Nat. Chem. Biol. 2010 6 25 33 10.1038/nchembio.275 19966789 PMC2901172
103. Diegelmann R.F. Cohen I.K. McCoy B.J. Growth kinetics and collagen synthesis of normal skin, normal scar and keloid fibroblasts in vitro J. Cell. Physiol. 1979 98 341 346 10.1002/jcp.1040980210 422662
104. Khaw P.T. Chang L. Wong T.T. Mead A. Daniels J.T. Cordeiro M.F. Modulation of wound healing after glaucoma surgery Curr. Opin. Ophthalmol. 2001 12 143 148 10.1097/00055735-200104000-00011 11224722
105. Jung J.L. Isida-Llerandi C.G. Lazcano-Gomez G. SooHoo J.R. Kahook M.Y. Intraocular Pressure Control after Trabeculectomy, Phacotrabeculectomy and Phacoemulsification in a Hispanic Population J. Curr. Glaucoma. Pract. 2014 8 67 74 10.5005/jp-journals-10008-1164 26997812 PMC4741170
106. Palanca-Capistrano A.M. Hall J. Cantor L.B. Morgan L. Hoop J. WuDunn D. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery Ophthalmology 2009 116 185 190 10.1016/j.ophtha.2008.08.009 18930550
107. Conlon R. Saheb H. Ahmed I.I.K. Glaucoma treatment trends: A review Can. J. Ophthalmol. 2017 52 114 124 10.1016/j.jcjo.2016.07.013 28237137
108. Sung M.S. Eom G.H. Kim S.J. Kim S.Y. Heo H. Park S.W. Trichostatin A Ameliorates Conjunctival Fibrosis in a Rat Trabeculectomy Model Investig. Ophthalmol. Vis. Sci. 2018 59 3115 3123 10.1167/iovs.18-23826 30025124
109. Fitzgerald O’Connor E.J. Badshah I.I. Addae L.Y. Kundasamy P. Thanabalasingam S. Abioye D. Soldin M. Shaw T.J. Histone deacetylase 2 is upregulated in normal and keloid scars J. Investig. Dermatol. 2012 132 1293 1296 10.1038/jid.2011.432 22205303
110. Russell S.B. Russell J.D. Trupin K.M. Gayden A.E. Opalenik S.R. Nanney L.B. Broquist A.H. Raju L. Williams S.M. Epigenetically altered wound healing in keloid fibroblasts J. Investig. Dermatol. 2010 130 2489 2496 10.1038/jid.2010.162 20555348 PMC2939920
111. Diao J.S. Xia W.S. Yi C.G. Yang Y. Zhang X. Xia W. Shu M.G. Wang Y.M. Gui L. Guo S.Z. Histone deacetylase inhibitor reduces hypertrophic scarring in a rabbit ear model Plast. Reconstr. Surg. 2013 132 61e 69e 10.1097/PRS.0b013e318290f698 23806955
112. Stubbs M.C. Kim W. Bariteau M. Davis T. Vempati S. Minehart J. Witkin M. Qi J. Krivtsov A.V. Bradner J.E. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Clin. Cancer Res. 2015 21 2348 2358 10.1158/1078-0432.CCR-14-1290 25688158 PMC4433811
113. Zimberlin C.D. Lancini C. Sno R. Rosekrans S.L. McLean C.M. Vlaming H. van den Brink G.R. Bots M. Medema J.P. Dannenberg J.H. HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis FASEB J. 2015 29 2070 2080 10.1096/fj.14-257931 25648995
114. Butler K.V. Kalin J. Brochier C. Vistoli G. Langley B. Kozikowski A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 2010 132 10842 10846 10.1021/ja102758v 20614936 PMC2916045
115. Kwon D.H. Eom G.H. Ko J.H. Shin S. Joung H. Choe N. Nam Y.S. Min H.K. Kook T. Yoon S. MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification Nat. Commun. 2016 7 10492 10.1038/ncomms10492 26832969 PMC4740400